Clinical Trial

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons. Thus, the investigators supposed that CD19/CD22 bispecific CAR-T cell therapy would be more effective and less relapses would occur in B- NHL. In this prospective phase 2 clinical trial, the investigators aim to explore the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in relapsed/refractory Large B cell lymphoma.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-23
notable Primary completion moved earlier: 2026-12-31 -> 2026-04-18 2026-04-23
Trial Details
NCT Number NCT07461831
Lead Sponsor Beijing Tongren Hospital
Conditions Large B-Cell Lymphoma (LBCL)
Enrollment 100 participants
Start Date 2022-02-01
Primary Completion 2026-04-18 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-22